10.21147/j.issn.1000-9604.2019.06.04
Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
31
2020-04-29(万方平台首次上网日期,不代表论文的发表时间)
共14页
878-891